Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
Revelation Biosciences Inc. Presents Additional Positive Data from Prime Clinical Study
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
Why Did Revelation Biosciences (REVB) Stock Jump Over 25% After-Hours?
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data